Figure 7
![Figure 7. Inhibition of NF-κB sensitizes BCR-ABL1–transformed B lymphoblasts to TKIs. (A) BCR-ABL1/GFP– or BCR-ABL1/IκBαSR–transformed primary B-lymphoid progenitors (4 × 104 cells per well) were incubated with different concentration of imatinib as indicated. Cell viability was determined by MTS assay after 96 hours’ incubation. (B-C) Equal numbers of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IKKαKM, or BCR-ABL1/IKKβKM were incubated with different concentration of imatinib (B) or dasatinib (C) as indicated. Cell viability was determined by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay after 96 hours’ incubation. Sigmoidal curves were fitted and IC50 values calculated by Prism software.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/15/10.1182_blood-2014-01-547943/4/2401f7.jpeg?Expires=1735562238&Signature=2f1WQ~jcAF4NnAvzXbsEvhZ3aU1YEUyHg-n3zTdtbMa6ZzPr-bHZTMK15ifcUJRL8j8nuWYmRa0tRbZKifFebVj~69Qle0xRPgiBPzHKpezFp8PdGJOP7gEYCkU9QqpvcD~F2n2xCWSju6PGsEnZMBOtchbt4M8KqJXbFL5O6o9qAe77b~fvYH9fCdlRdKNheogAsrbv8rX~wIGGNJpc78EM214fcxNd0vlw-rrZA65w-G0~Q5nrHLrJW-WBLjTGYxvwIjHNt9PtYi9RaHViQwJqlriCe~t3wQs8kBOPvgyZe~0NWGNXTDE9-C91yedzJyA41FKzqJlTBSxaBRi8IQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Inhibition of NF-κB sensitizes BCR-ABL1–transformed B lymphoblasts to TKIs. (A) BCR-ABL1/GFP– or BCR-ABL1/IκBαSR–transformed primary B-lymphoid progenitors (4 × 104 cells per well) were incubated with different concentration of imatinib as indicated. Cell viability was determined by MTS assay after 96 hours’ incubation. (B-C) Equal numbers of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IKKαKM, or BCR-ABL1/IKKβKM were incubated with different concentration of imatinib (B) or dasatinib (C) as indicated. Cell viability was determined by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay after 96 hours’ incubation. Sigmoidal curves were fitted and IC50 values calculated by Prism software.
